|
Moksha8
|
|
moksha8 is a pharmaceutical company in Latin America that was founded in 2007 by CEO, Simba Gill and the Texas Pacific Group ("TPG") Biotechnology Fund. moksha8 commercializes products to treat various central nervous system, infectious disease and pain indications. In 2008, the Company established partnerships with Roche and Pfizer in Brazil to commercialize a portfolio of over 20 products. In 2009, moksha8 expanded its partnership with Roche to establish operations in Mexico and assume commercialization of products selling over $125M USD. Also in 2009, moksha8 established a partnership with US Biotechnology company BioCryst for commercialization of the anti-viral Peramivir to treat severe H1N1 influenza. Products in moksha8's portfolio include well name brands including: Rivotril®, Lexotan®, Bactrim®, Rocephin®, Peramivir® and Mesulid®. moksha8 has commercial operations in Sao Paulo, Brazil and Mexico City, Mexico with over 200 employees. moksha8's US headquarters is based near Philadelphia, PA. It has received venture funding from Simba Gill, TPG, Montreux Equity Partners and Votorantim Novo Negocios. 
|
| < Prev | Next > |
|---|
Main Menu
| Home |
| Articles |
| Search |
| Submit Article |
| Contact Us |
| Donate to Wikibin |
